Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer.

ABSTRACT:

Background

Sacituzumab govitecan (SG) is an anti-trop2 antibody-drug conjugate (ADC) approved for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, data on effectiveness of SG and biomarkers remain limited. DNADX is a plasma-only multi-gene signature assay that identifies five tumor subtypes. In previous studies, DNADX subtypes have been associated with clinical outcomes.

Materials and methods

This study included patients with MBC treated with SG monotherapy between June 2014 and January 2023. Clinicopathological features and outcomes [time to next treatment (TTNT), overall survival (OS)] were analyzed. An exploratory analysis evaluated the association between DNADX subtypes and outcomes.

Results

A total of 121 patients

SUBMITTER: Morganti S 

PROVIDER: S-EPMC12514483 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature